Vor Bio日前公布其在研干细胞疗法tremtelectogeneempogeditemcel（trem-cel）与CD33靶向抗体偶联药物（ADC）Mylotarg联用，治疗复发/难治性 ...

In the chemical world, the tiny hyphen in antibody-drug conjugates—or ADCs, as they’re commonly known—does a lot more work ...

Vor Biopharma Inc. (NASDAQ:VOR) announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed ...

自上市以来股价跌跌不休的Vor Bio (VOR.US)似乎迎来“超级反转”，该公司股票价格在周四美股盘后交易中一度暴涨超70%，此前该公司报告了其基因编辑干细胞疗法 trem-cel 治疗急性髓性白血病 (AML) 的积极数据。基因编辑干细胞疗法trem-cel与 Mylotarg 联合治疗急性髓性白血病的1/2期试验数据积极，显示出联合疗效和药物安全性潜力。

PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies ...

The data demonstrated reliable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic window, and early evidence of patient benefit. The full text of the ...

Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging ...

Pfizer’s Mylotarg is back on the US market after a seven-year absence, after the FDA reapproved it in the aggressive blood cancer, acute myeloid leukaemia. The world’s first approved antibody ...